338 related articles for article (PubMed ID: 31849951)
21. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
[TBL] [Abstract][Full Text] [Related]
22. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.
Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB
Front Immunol; 2018; 9():967. PubMed ID: 29867949
[TBL] [Abstract][Full Text] [Related]
23. Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis.
Foroughi-Parvar F; Hatam GR; Sarkari B; Kamali-Sarvestani E
Immunotherapy; 2015; 7(1):3-12. PubMed ID: 25572475
[TBL] [Abstract][Full Text] [Related]
24. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
Stäger S; Smith DF; Kaye PM
J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
[TBL] [Abstract][Full Text] [Related]
26. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.
Bhowmick S; Ravindran R; Ali N
BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931
[TBL] [Abstract][Full Text] [Related]
27. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.
Costa LE; Goulart LR; Pereira NC; Lima MI; Duarte MC; Martins VT; Lage PS; Menezes-Souza D; Ribeiro TG; Melo MN; Fernandes AP; Soto M; Tavares CA; Chávez-Fumagalli MA; Coelho EA
PLoS One; 2014; 9(10):e110014. PubMed ID: 25333662
[TBL] [Abstract][Full Text] [Related]
28. Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice.
Amit A; Vijayamahantesh ; Dikhit MR; Singh AK; Kumar V; Suman SS; Singh A; Kumar A; Thakur AK; Das VR; Das P; Bimal S
Mol Immunol; 2017 Feb; 82():104-113. PubMed ID: 28064069
[TBL] [Abstract][Full Text] [Related]
29. Histopathological and immunohistochemical characterisation of hepatic granulomas in Leishmania donovani-infected BALB/c mice: a time-course study.
Salguero FJ; Garcia-Jimenez WL; Lima I; Seifert K
Parasit Vectors; 2018 Jan; 11(1):73. PubMed ID: 29386047
[TBL] [Abstract][Full Text] [Related]
30. Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity.
Saini S; Ghosh AK; Das S; Singh R; Abhishek K; Verma S; Kumar A; Mandal A; Purkait B; Sinha KK; Das P
Vaccine; 2018 Feb; 36(9):1190-1202. PubMed ID: 29395522
[TBL] [Abstract][Full Text] [Related]
31. Vaccine potential of HLA-A2 epitopes from Leishmania Cysteine Protease Type III (CPC).
Dikhit MR; Amit A; Singh AK; Kumar A; Mansuri R; Sinha S; Topno RK; Mishra R; Das VNR; Pandey K; Sahoo GC; Ali V; Bimal S; Das P
Parasite Immunol; 2017 Sep; 39(9):. PubMed ID: 28665520
[TBL] [Abstract][Full Text] [Related]
32. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.
Dey R; Dagur PK; Selvapandiyan A; McCoy JP; Salotra P; Duncan R; Nakhasi HL
J Immunol; 2013 Mar; 190(5):2138-49. PubMed ID: 23338240
[TBL] [Abstract][Full Text] [Related]
33. Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
Ribeiro PAF; Vale DL; Dias DS; Lage DP; Mendonça DVC; Ramos FF; Carvalho LM; Carvalho AMRS; Steiner BT; Roque MC; Oliveira-da-Silva JA; Oliveira JS; Tavares GSV; Galvani NC; Martins VT; Chávez-Fumagalli MA; Roatt BM; Moreira RLF; Menezes-Souza D; Oliveira MC; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
Cytokine; 2020 May; 129():155031. PubMed ID: 32062145
[TBL] [Abstract][Full Text] [Related]
34. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
[TBL] [Abstract][Full Text] [Related]
35. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
Thakur A; Kaur H; Kaur S
Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
[TBL] [Abstract][Full Text] [Related]
36. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
[TBL] [Abstract][Full Text] [Related]
37. A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis.
Ribeiro PAF; Dias DS; Novais MVM; Lage DP; Tavares GSV; Mendonça DVC; Oliveira JS; Chávez-Fumagalli MA; Roatt BM; Duarte MC; Menezes-Souza D; Ludolf F; Tavares CAP; Oliveira MC; Coelho EAF
Cytokine; 2018 Nov; 111():131-139. PubMed ID: 30142534
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection.
Ribeiro PAF; Dias DS; Lage DP; Martins VT; Costa LE; Santos TTO; Ramos FF; Tavares GSV; Mendonça DVC; Ludolf F; Gomes DA; Rodrigues MA; Chávez-Fumagalli MA; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
Mol Immunol; 2019 Feb; 106():108-118. PubMed ID: 30594673
[TBL] [Abstract][Full Text] [Related]
39. Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice.
Santos TTO; Martins VT; Lage DP; Costa LE; Salles BCS; Carvalho AMRS; Dias DS; Ribeiro PAF; Chávez-Fumagalli MA; Machado-de-Ávila RA; Roatt BM; de Magalhães-Soares DF; Menezes-Souza D; Coelho EAF; Duarte MC
Acta Trop; 2017 Jul; 171():8-16. PubMed ID: 28288798
[TBL] [Abstract][Full Text] [Related]
40. Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis.
Dias DS; Ribeiro PAF; Martins VT; Lage DP; Portela ÁSB; Costa LE; Salles BCS; Lima MP; Ramos FF; Santos TTO; Caligiorne RB; Chávez-Fumagalli MA; Silveira JAG; Magalhães-Soares DF; Gonçalves DU; Oliveira JS; Roatt BM; Duarte MC; Menezes-Souza D; Silva ES; Galdino AS; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
Mol Immunol; 2017 Nov; 91():272-281. PubMed ID: 28988041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
